跳至主要内容
临床试验/EUCTR2013-001003-36-IT
EUCTR2013-001003-36-IT进行中(未招募)1 期

The DIAMOND® for the Treatment of Type 2 Diabetes: Can blood Triglycerides level be the predictor for therapy efficiency? - DIAMOND

METACURE LIMITED0 个研究点目标入组 59 人开始时间: 2021年1月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
59

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects 18 through 70 years of age, overweight and obese, Type 2 diabetes, with a body mass index (BMI) of 30 to 45 (kg/m2) and poor glycemic control defined as HbA1c = 7.3% and = 9.5% and fasting blood glucose (FBG) between 120-350 mg/dL.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 7
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 3

排除标准

  • Insulin therapy in last 3 months; Taking GLP-1 agonists or in the last 3 months before the enrollment; Currently taking fibrates, nicotinamide and omega 3 fatty acids as antilipidemic treatment; any condition(s) for which it is contraindicated the possible intake of fenofibrate.

研究者

发起方
METACURE LIMITED

相似试验